BENGALURU: Leading biotech major Biocon's subsidiary company Biocon Biologics Ltd on Monday said it would make an antibody in collaboration with the US-based Adagio Therapeutics to treat Covid symptoms. "Adagio has granted an exclusive license to us to manufacture and market an antibody for treating Covid in India and select emerging markets," said the city-based integrated biosimilars firm in a statement.
The drug (ADG20) is a novel monoclonal antibody can enable outpatient administration as a single injection to prevent and treat Covid symptoms. The drug targets the spike protein of Sars-CoV-2 and related coronaviruses. It is in global clinical development by Adagio as an agent to treat and prevent Covid. The drug has been designed and engineered to have high potency for neutralizing the infection. "The drug has the potential to impact viral replication and subsequent disease through multiple mechanisms of action," said the company. "The antibody has a long half-life, which allows for immediate and durable protection against Covid up to 1 year," added the statement.
Study reveals- Vaccination gives 97.4 pc protection from COVID-19
Scientists give warning on Resurgence of Respiratory Viruses in Young Children
How new Atlas charts antibodies attack spike protein of Covid variants